Ide Smets retweeted
@drruthdobson (UK) and @SmetsIde (The Netherlands) explore the practicalities of therapeutic sequencing options in MS.
Watch now: ow.ly/FTEX50OMQV5
#MedTwitter #Neurology #NeuroImmunology #MS #MultipleSclerosis #MedEd
Ide Smets retweeted
Controversy āļø
Pre-symptomatic #MultipleSclerosis or radiologically isolated syndrome #RIS should be actively monitored and treated.
š§µ1/4
Link to commentary ā¶ļø journals.sagepub.com/doi/absā¦
Not all MS drugs are created equal! In MS Center ErasMS gebruiken we daarom vanaf nu de Nederlandse versie van de #clinicspeak medicatie keuzetool. Vrij beschikbaar voor alle MS centra en pmMS. DM voor een visitekaartje! clinicspeak.com/dmt/nl
Ide Smets retweeted
This is a vastly improved tool to help make the best DMT choices.
clinicspeak.com/dmt/
Question 2 is a real no-brainer!
Kudos to @SmetsIde
Ide Smets retweeted
Past & current #BartsMS @ectrims fellows @SmetsIde Drs Saul Reyes & Manuel Salavisa linking up with @preventiveneur1 senior lecturer @somehow_related at #ECTRIMS2022 @Iamsterdam
Very š„ debate with @XtineLebrunF and @drBWillekens on a late breaking topic: should we start treating radiologically isolated syndrome? A struggle between biology and disease, that needs to be addressed by new RIS criteria. @ECTRIMS
In simulated MS cohorts, lesion detection algorithms argue to be disease-modifying by detection more lesions, triggering early treatment switches and preventing disability. Nice feature or necessary add-on intervention?
multiple-sclerosis-research.ā¦
Ide Smets retweeted
Russians: Do you want to join Holland?
(Namens Nederland, een referendum voor alle Russen: willen jullie bij Nederland horen?)
Rituximab (anti-CD20) is a more potent MS drug than dimethyl fumarate. The bigger question: is it better than the more costly ocrelizumab? Three possible answers: an official, a real and a right one. Which one do you prefer?@the_MSBlog multiple-sclerosis-research.ā¦
Thereās no exit strategy for pwMS on anti-CD20 atm. Some argue thereās no need to exit, some argue to extend intervals and we argue to stop anti-CD20 after 4 infusion cycli. Do you agree? journals.sagepub.com/doi/10.ā¦ @ErasMS_Rdam
The position of aHSCT in the MS treatment landscape is a source of debate, and for many pwMS itās unclear who can benefit. In early aggressive MS itās clear, but for progressive MS the risk/benefit profile of aHSCT shifts. @the_MSBlog multiple-sclerosis-research.ā¦
During clincics, we are often too much focused on drugs, and forget to mention the second most-effective MS treatment: exercise. To compensate, I discuss my insights together with @themsguide in this podcast. #brainhealth
open.spotify.com/episode/0bKā¦
Many pwMS need to gain a new expertise: overcoming administrative hurdles to gain access to crucial healthcare services such as rehab. In the UK this is the red tape, in the Netherlands a purple crocodile. Do you have any in your pool? multiple-sclerosis-research.ā¦ @ErasMS_Rdam
Ide Smets retweeted
This is a superb post. I also struggle to understand why someone would fail to take the neurologist's advice. I guess @SmetsIde has put her finger on it when she suggests it may be a form of denial (my words).
MS is constantly vandalising our brains.
bit.ly/3vPXS4f
Many pwMS struggle with DMT decisions when they have new lesions on brain MRI without new symptoms. Two attempts to better explain this clinical-MRI paradox: the topographical model of MS and road traffic. Do you stop for groceries at night? @the_MSBlog multiple-sclerosis-research.ā¦
Ide Smets retweeted
Are the Dutch also ready to embrace HSCT as a first line treatment? @MSwebNL @msvereniging @MS_Research @NationalMSFonds @ErasMS_Rdam @Hersenbank @MScentrum020 @GTCumcg @nvneuropsy @SmetsIde @JeroenJGGeurts @HannekeHulst @Eef111 @NIN_knaw
Great debate about #AHSCT for #MS first lineat #CONy2022. āHematopoietic stem cell therapies (HSCT) should be offered as a first line DMT in selected MSĀ patients: NO?ā I am glad to report that I lost the debate. #neurologist are ready to embrace #AHSCT. @Boaz_Spermon @AANMember
Ide Smets retweeted
A huge thanks to all the people with MS who helped us to design this leaflet for people with MS considering pregnancy buff.ly/3tB3xKb. You had told us you wanted a reliable leaflet to be able to look at outside of clinic appointments that you could read in your own time.
Serum NfL Z-scores instead of raw cut-offs are much better at predicting inflammatory disease activity in pwMS. An online tool allows to use Z-scores for DMT decisions in daily practice. Can we now flip and zip the DMT pyramid? multiple-sclerosis-research.ā¦
We cannot prescribe anti-CD20 indefinitely, and thereās considerable evidence to start using it as an induction therapy. Understandably, many pwMS are not prepared to let go of the 6-monthly infusions. Would you be prepared to stop? @the_MSBlog multiple-sclerosis-research.ā¦
A German cohort showed that two thirds of female pwMS stopping natalizumab because of pregnancy have a relapse, and 10% keeps disability one year after delivery. Numbers that make PML risk look good. Time to change the expert advice? multiple-sclerosis-research.ā¦ @the_MSBlog